ApconiX Welcomes Dr Karin Burnett to The Team

ApconiX is delighted to welcome Dr Karin Burnett, an experienced project toxicologist with a broad knowledge of toxicology and chemical risk assessment in the pharmaceutical industry.  Karin will join the team of experts in nonclinical safety toxicology at ApconiX, who cover all major safety disciplines and are committed to advancing the science of drug safety.

Karin Burnett graduated from the University of Surrey with a BSc in Biochemistry (Toxicology).  She attained her Diploma from the Institute of Biology in Toxicology (DIBT) and then went on to study for a PhD at the University of Birmingham, investigating mechanisms of liver non-genotoxic carcinogenesis.

Karin has extensive experience in the area having worked for a number of pharmaceutical companies including Zeneca, SmithKline Beechams and Shire Pharmaceuticals.  More recently Karin has worked with Public Health England and Imperial College, London (Toxicology Unit) as a scientific writer compiling detailed literature reviews on a wide variety of subjects for the government advisory Committees on Carcinogenicity (COC) and Mutagenicity (COM).

Karin joins the team to work in project toxicology and on target safety assessments, “I am looking forward to working with such a skilled team at ApconiX and bringing my own comprehensive experience of nonclinical programme strategy development to the team.”

Professor Ruth Roberts added, “We are very excited to have Karin on board.  With such a broad experience of toxicology, she will provide input into many aspects of the business especially Target Safety Assessments and other expert scientific reports.  It is vital to understand the potential unintended consequences of target modulation and Target Safety Reports form a key part of risk assessment and risk mitigation plans in drug discovery and development.”